

Heinz Ludwig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3977134/publications.pdf>

Version: 2024-02-01

315
papers

24,400
citations

12328

69
h-index

7744

150
g-index

326
all docs

326
docs citations

326
times ranked

15022
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice. Cancer Reports, 2022, 5, e1429.	1.4	7
2	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology, the, 2022, 9, e143-e161.	4.6	44
3	Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1,). Tj ETQq11b0.784314 rgBT, 2022, 10, 100784314.	11.0	784314
4	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	7.2	79
5	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
6	Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma. Haematologica, 2021, 106, 2516-2521.	3.5	5
7	Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Research, 2021, 81, 4581-4593.	0.9	8
8	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. American Journal of Hematology, 2021, 96, 896-900.	4.1	12
9	Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience. HemaSphere, 2021, 5, e597.	2.7	4
10	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	3.5	22
11	Myeloma research on the move. Blood Cancer Journal, 2021, 11, 155.	6.2	2
12	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25
13	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Advances, 2021, 5, 4125-4139.	5.2	6
14	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology, the, 2021, 8, e934-e946.	4.6	46
15	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study). Blood, 2021, 138, 1669-1669.	1.4	0
16	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. Blood, 2021, 138, 4725-4725.	1.4	0
17	Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. Quality of Life Research, 2020, 29, 69-79.	3.1	13
18	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leukemia and Lymphoma, 2020, 61, 377-386.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.4	75
20	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020, 34, 224-233.	7.2	122
21	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. <i>Leukemia and Lymphoma</i> , 2020, 61, 37-46.	1.3	6
22	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	5.2	17
23	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020, 13, 173.	17.0	91
24	Daratumumab: a game changer in myeloma therapy. <i>Lancet Haematology</i> , 2020, 7, e426-e427.	4.6	6
25	Highlights of ASH 2019 multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 270-275.	0.5	1
26	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e456-e468.	4.6	244
27	The anti-mitotic agents PTC028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. <i>British Journal of Haematology</i> , 2020, 190, 877-890.	2.5	15
28	Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. <i>Oncologist</i> , 2020, 25, e1406-e1413.	3.7	81
29	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
30	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
31	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study). <i>Blood</i> , 2020, 136, 29-30.	1.4	0
32	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). <i>Blood</i> , 2020, 136, 27-29.	1.4	0
33	Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 673-682.	0.6	2
34	Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. <i>British Journal of Cancer</i> , 2019, 121, 751-757.	6.4	17
35	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
36	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , 2019, 20, e302-e312.	10.7	290

#	ARTICLE	IF	CITATIONS
37	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 522-530.e1.	0.4	47
38	Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. Future Oncology, 2019, 15, 897-907.	2.4	9
39	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 23.	6.2	32
40	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	3.5	18
41	The first-in-class BMI-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e113-e114.	0.4	0
42	Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e31-e32.	0.4	1
43	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood, 2019, 133, 147-155.	1.4	33
44	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day (<24h), <per-guidelines>(24-72h), and <late>(≥72h): findings from the MONITOR-GCSF study. Supportive Care in Cancer, 2019, 27, 2301-2312.	0.2	22
45	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
46	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq 0 0 0 rgBT /Overlock 10 Tf 5 Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	1.4	4
47	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. Blood, 2019, 134, 3066-3066.	1.4	2
48	Other Complications of Multiple Myeloma. Hematologic Malignancies, 2018, , 141-156.	0.2	1
49	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
50	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia, 2018, 32, 2032-2036.	7.2	12
51	Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 2018, 59, 14-28.	1.3	17
52	Carfilzomib+dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma, 2018, 59, 1364-1374.	1.3	6
53	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	3.5	110
54	EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. Oncologist, 2018, 23, 631-636.	3.7	30

#	ARTICLE	IF	CITATIONS
55	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
56	Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. <i>Haematologica</i> , 2018, 103, 325-335.	3.5	23
57	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-734.	1.6	221
58	Update of clinical highlights presented at the 2017 American Society of Hematology Meeting. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 89-93.	0.5	0
59	Overall Survival of Patients Post-Transplant: Study Results from Two Phase 3 Trials ASPIRE and ENDEAVOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S238-S239.	0.4	0
60	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	3.5	86
61	Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. <i>Haematologica</i> , 2018, 103, 1359-1368.	3.5	14
62	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
63	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	3.5	70
64	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
65	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	7.2	83
66	Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 3210-3210.	1.4	3
67	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
68	Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma – AGMT_MM1. <i>Blood</i> , 2018, 132, 3275-3275.	1.4	0
69	Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2017, 25, 1819-1828.	2.2	20
70	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
71	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017, 129, 2359-2367.	1.4	44
72	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45

#	ARTICLE	IF	CITATIONS
73	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 2017, 58, 2501-2504.	1.3	22
74	Multiple myeloma: new treatments gain momentum. Lancet, The, 2017, 389, 480-482.	13.7	2
75	IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide+dexamethasone therapy in multiple myeloma. American Journal of Hematology, 2017, 92, 269-278.	4.1	11
76	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1327-1337.	10.7	320
77	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. European Journal of Haematology, 2017, 99, 449-458.	2.2	6
78	The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Oncologist, 2017, 22, 1339-1346.	3.7	12
79	Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e75.	0.4	1
80	Is there progress in the treatment of high-risk myeloma?. Memo - Magazine of European Medical Oncology, 2017, 10, 76-81.	0.5	1
81	Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). Journal of Geriatric Oncology, 2017, 8, 86-95.	1.0	22
82	Fixed duration vs continuous therapy in multiple myeloma. Hematology American Society of Hematology Education Program, 2017, 2017, 212-222.	2.5	24
83	Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. Blood, 2017, 130, 743-743.	1.4	16
84	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	10.9	34
85	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2016, 34, 3921-3930.	1.6	70
86	Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. American Journal of Hematology, 2016, 91, 295-301.	4.1	36
87	Early treatment for high-risk smouldering myeloma: has the time come?. Lancet Oncology, The, 2016, 17, 1030-1032.	10.7	0
88	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
89	Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. Journal of Hematology and Oncology, 2016, 9, 17.	17.0	41
90	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	10.7	723

#	ARTICLE	IF	CITATIONS
91	Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2516-2525.	1.3	18
92	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	3.7	28
93	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
94	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016, 24, 911-925.	2.2	62
95	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	1.4	11
96	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 242-242.	1.4	26
97	Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 309-309.	1.4	2
98	Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3309-3309.	1.4	8
99	Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial. <i>Blood</i> , 2016, 128, 3335-3335.	1.4	3
100	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	1.4	29
101	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	1.6	52
102	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 2134-2134.	1.4	0
103	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	1.4	0
104	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. <i>British Journal of Haematology</i> , 2015, 171, 344-354.	2.5	26
105	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
106	Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. <i>Haematologica</i> , 2015, 100, 385-391.	3.5	26
107	New drugs on the horizon. Treatment of myeloma in 2020, a perspective. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 16-21.	0.5	1
108	Tailoring treatment in myeloma: are there clues from biology?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 11-15.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 10.	17.0	24
110	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
111	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
112	Iron metabolism and iron supplementation in cancer patients. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 907-919.	1.9	108
113	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
114	Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1733-1733.	1.4	25
115	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	1.4	5
116	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	1.4	8
117	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	1.4	27
118	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	1.4	3
119	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	1.4	15
120	Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 1823-1823.	1.4	1
121	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. <i>Medical Oncology</i> , 2014, 31, 302.	2.5	32
122	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	3.5	124
123	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	3.5	185
124	Pharmacovigilance in practice: erythropoiesis-stimulating agents. <i>Cancer Medicine</i> , 2014, 3, 1416-1429.	2.8	2
125	Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation. <i>Leukemia and Lymphoma</i> , 2014, 55, 2520-2524.	1.3	16
126	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 11-18.	1.3	4

#	ARTICLE	IF	CITATIONS
127	Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2014, 123, 985-991.	1.4	92
128	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
129	A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. <i>Supportive Care in Cancer</i> , 2014, 22, 2197-2206.	2.2	31
130	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697
131	Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. <i>Experimental Hematology</i> , 2014, 42, 516-525.	0.4	25
132	Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis – A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 1-15.	4.4	63
133	Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2111-2111.	1.4	4
134	Lenalidomide and Dexamethasone for Acute Light Chain-Induced Renal Failure: Final Results of a Phase II Study. <i>Blood</i> , 2014, 124, 3484-3484.	1.4	1
135	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	1.4	15
136	CXCR3 Binding Chemokines MIG, IP-10 and ITAC Are Predictors of Overall Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 2052-2052.	1.4	0
137	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 247-255.	1.6	69
138	Modeling of treatment response to erythropoiesis-stimulating agents in older (age ≥ 70 years) and younger (age < 70 years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study. <i>Journal of Geriatric Oncology</i> , 2013, 4, 196-201.	1.0	0
139	High expression of cereblon (<i>CRBN</i>) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. <i>British Journal of Haematology</i> , 2013, 161, 695-700.	2.5	110
140	Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. <i>Annals of Oncology</i> , 2013, 24, 1886-1892.	1.2	179
141	Cereblon expression in multiple myeloma: not ready for prime time – Response to Lodigiani et al. <i>British Journal of Haematology</i> , 2013, 163, 285-286.	2.5	4
142	Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. <i>Leukemia</i> , 2013, 27, 213-219.	7.2	99
143	Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study. <i>Blood</i> , 2013, 122, 1951-1951.	1.4	3
144	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf (Pts) Ineligible For Stem Cell Transplantation (SCT). <i>Blood</i> , 2013, 122, 2-2.	1.4	39

#	ARTICLE	IF	CITATIONS
145	Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. Blood, 2013, 122, 3439-3439.	1.4	6
146	Vemurafenib Inhibits Myeloma Cell Growth Independent Of BRAF V600E Mutations, Potentiates The Activity Of Established Anti-Myeloma Drugs, but Impairs Osteogenesis Via An HGF Autocrine Loop In Bone Marrow Stromal Cells. Blood, 2013, 122, 5363-5363.	1.4	2
147	Isotype Matched Paired Immunoglobulin Suppression Identifies High Risk Multiple Myeloma Patients and Is Independent Of Bone Marrow Infiltration Suggesting Significant Variability In The HLC Matched Pair Suppressive Activity Of Individual Myeloma Clones. Blood, 2013, 122, 5352-5352.	1.4	0
148	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. Oncologist, 2012, 17, 592-606.	3.7	48
149	Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. Clinical Cancer Research, 2012, 18, 2145-2163.	7.0	38
150	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2475-2482.	1.6	185
151	IMWG consensus on maintenance therapy in multiple myeloma. Blood, 2012, 119, 3003-3015.	1.4	178
152	Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1821-1830.	2.5	12
153	Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?. Leukemia Research, 2012, 36, S27-S34.	0.8	9
154	Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.5	1
155	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	7.2	664
156	Myeloma Genetics International Consortium. Leukemia and Lymphoma, 2012, 53, 796-800.	1.3	7
157	Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. Lung Cancer, 2012, 76, 478-485.	2.0	40
158	Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9Åg/dL versus 9 to <10Åg/dL versus ≥10Åg/dL: an exploratory analysis of a phase 3 trial. Medical Oncology, 2012, 29, 2291-2299.	2.5	14
159	Treatment outcome in AML: a single-centre experience in an unselected patient cohort. Memo - Magazine of European Medical Oncology, 2012, 5, 134-140.	0.5	1
160	Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. European Journal of Clinical Investigation, 2012, 42, 953-960.	3.4	79
161	Usage of HLC-Ratio, FLC-Ratio, Ife, PBMC Infiltration and Isotype Suppression At Best Response Reveals Isotype Suppression As Most Powerful Parameter for Identification of Multiple Myeloma Patients with Long Survival. Blood, 2012, 120, 1817-1817.	1.4	2
162	Treatment with Bendamustine-Bortezomib-Dexamethasone (BBD) in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated. Blood, 2012, 120, 943-943.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF). Blood, 2012, 120, 4031-4031.	1.4	0
164	Intact Immunoglobulin or Fragments Thereof Can Be Detected in Urine in a Proportion of Patients with Multiple Myeloma and Are Associated with Reduced Survival At Presentation. Blood, 2012, 120, 1828-1828.	1.4	0
165	Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequences for Myeloma Cell Growth and Bone Disease. Blood, 2012, 120, 3947-3947.	1.4	2
166	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 2011, 117, 4701-4705.	1.4	377
167	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	7.7	66
168	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	1.4	849
169	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	1.4	282
170	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	1.4	309
171	Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. British Journal of Haematology, 2011, 154, 325-336.	2.5	150
172	Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Critical Reviews in Oncology/Hematology, 2011, 77, 184-197.	4.4	23
173	Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Critical Reviews in Oncology/Hematology, 2011, 77, 198-200.	4.4	15
174	Patient With High-Grade Fever, Night Sweats, and Hepatosplenomegaly. Journal of Clinical Oncology, 2011, 29, e254-e256.	1.6	1
175	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 2011, 16, 388-403.	3.7	26
176	Supportive Therapy in Multiple Myeloma. Recent Results in Cancer Research, 2011, 183, 307-333.	1.8	4
177	High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone. Blood, 2011, 118, 2879-2879.	1.4	5
178	Serum Heavy/Light Chain and Free Light Chain Measurements Provide Prognostic Information, Allow Creation of a Prognostic Model and Identify Clonal Changes (clonal tiding) Through the Course of Multiple Myeloma (MM). Blood, 2011, 118, 2883-2883.	1.4	4
179	Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between Patients and Physicians. Blood, 2011, 118, 2928-2928.	1.4	1
180	Rapid Reduction of Light-Chains and Proteinuria in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure Treated with Lenalidomide and Dexamethasone. Blood, 2011, 118, 5114-5114.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury,. Blood, 2011, 118, 3949-3949.	1.4	0
182	Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis,. Blood, 2011, 118, 3340-3340.	1.4	1
183	Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica, 2010, 95, 1548-1554.	3.5	75
184	Threatening clots in MGUS and myeloma. Blood, 2010, 115, 4975-4976.	1.4	4
185	BMP-2: a culprit for anemia in myeloma. Blood, 2010, 116, 3383-3384.	1.4	4
186	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 1599-1605.	1.6	142
187	Energy consumption of reverse osmosis seawater desalination - possibilities for its optimisation in design and operation of SWRO plants. Desalination and Water Treatment, 2010, 13, 13-25.	1.0	27
188	Author reply: Lenalidomide for bortezomib-resistant multiple myeloma. Nature Reviews Clinical Oncology, 2010, 7, 1-1.	27.6	0
189	Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nature Reviews Clinical Oncology, 2010, 7, 289-294.	27.6	16
190	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. Oncologist, 2010, 15, 6-25.	3.7	85
191	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2006-2011.	1.3	14
192	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	1.6	358
193	Light Chain-Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. Journal of Clinical Oncology, 2010, 28, 4635-4641.	1.6	133
194	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology, The, 2010, 11, 1086-1095.	10.7	187
195	Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anti-Cancer Drugs, 2010, 21, 708-715.	1.4	8
196	Current Practice In Diagnosis and Treatment of Chemotherapy-Induced Anemia In Five European Countries – A Patient Record Study. Blood, 2010, 116, 1512-1512.	1.4	2
197	Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation. Blood, 2010, 116, 3043-3043.	1.4	1
198	The Ratio of Monoclonal to Polyclonal Immunoglobulins Assessed with the Hevylite Test Predicts Prognosis, Is Superior for Monitoring the Course of the Disease and Allows Detection of Monoclonal Immunoglobulin In Patients with Normal or Subnormal Involved Immunoglobulin Isotype. Blood, 2010, 116, 4038-4038.	1.4	2

#	ARTICLE	IF	CITATIONS
199	High Prevalence of Iron Deficiency In Anemic and Non Anemic Patients with Various Types of Cancer. Blood, 2010, 116, 5145-5145.	1.4	0
200	Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma. OncoTargets and Therapy, 2009, 2, 199.	2.0	7
201	Reply to G. Ferretti et al. Journal of Clinical Oncology, 2009, 27, e212-e212.	1.6	0
202	Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia. Journal of Clinical Oncology, 2009, 27, 2838-2847.	1.6	129
203	Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥ 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer, 2009, 9, 311.	2.6	22
204	A reply to Efficacesâ€™ letter to the editor. European Journal of Haematology, 2009, 82, 486-487.	2.2	0
205	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews, 2009, 23, 87-93.	5.7	35
206	Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. European Journal of Cancer, 2009, 45, 1603-1615.	2.8	54
207	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood, 2009, 114, 1729-1735.	1.4	203
208	Management of Complications in Multiple Myeloma. Seminars in Hematology, 2009, 46, 176-189.	3.4	26
209	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 2009, 113, 3435-3442.	1.4	213
210	Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.. Blood, 2009, 114, 2312-2312.	1.4	4
211	Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study.. Blood, 2009, 114, 3862-3862.	1.4	4
212	Abnormal Serum IgA Kappa / IgA Lambda Ratios at Maximum Response Predict Poor Progression Free Survival in Myeloma Patients.. Blood, 2009, 114, 4879-4879.	1.4	1
213	Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis.. Blood, 2009, 114, 2871-2871.	1.4	1
214	Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.. Blood, 2009, 114, 2891-2891.	1.4	0
215	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Supportive Care in Cancer, 2008, 16, 193-200.	2.2	15
216	Successful treatment of a patient with lymphocyteâ€predominant Hodgkinâ€™s lymphoma with yttriumâ€90â€ibritumomab tiuxetan. European Journal of Haematology, 2008, 81, 322-324.	2.2	5

#	ARTICLE	IF	CITATIONS
217	Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. European Journal of Haematology, 2008, 81, 374-379.	2.2	44
218	Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111, 3968-3977.	1.4	294
219	Erythropoietins should be used according to guidelines. Lancet Oncology, The, 2008, 9, 412-413.	10.7	27
220	Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Oncology, 2008, 26, 1040-1050.	1.6	197
221	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood, 2008, 111, 4039-4047.	1.4	190
222	Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study. Blood, 2008, 112, 3682-3682.	1.4	4
223	Prevalence and incidence of anemia and risk factors for anemia in patients with cancer. , 2008, , 189-206.		0
224	Double Transplantation with Melphalan (200 mg/m ²) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m ²) in Patients with Multiple Myeloma. Blood, 2008, 112, 3317-3317.	1.4	0
225	Management of Anemia in Multiple Myeloma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study. Blood, 2008, 112, 4716-4716.	1.4	0
226	Management of Anemia in Patients with Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study. Blood, 2008, 112, 4672-4672.	1.4	0
227	Comparison of the Management of Anemia in Patients with Solid Versus Hematological Malignancies Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study. Blood, 2008, 112, 4715-4715.	1.4	0
228	Management of Anemia in Lymphoma Patients Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from the European Anemia Cancer Treatment (A.C.T.) Study. Blood, 2008, 112, 4706-4706.	1.4	0
229	Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study. Blood, 2008, 112, 5195-5195.	1.4	1
230	Is bortezomib active in patients with mantle cell lymphoma?. Nature Clinical Practice Oncology, 2007, 4, 276-277.	4.3	0
231	Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica, 2007, 92, 1411-1414.	3.5	124
232	Supportive care in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 817-835.	1.7	28
233	A Survey among Oncologists on Measures Needed to Improve Cancer Care. Oncology Research and Treatment, 2007, 30, 367-372.	1.2	1
234	“œLaying on of hands” improves well-being in patients with advanced cancer. Supportive Care in Cancer, 2007, 15, 143-151.	2.2	19

#	ARTICLE	IF	CITATIONS
235	The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Supportive Care in Cancer, 2007, 15, 265-272.	2.2	10
236	Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.. Blood, 2007, 110, 3603-3603.	1.4	10
237	Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.. Blood, 2007, 110, 529-529.	1.4	17
238	Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.. Blood, 2007, 110, 4086-4086.	1.4	7
239	Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leukemia and Lymphoma, 2006, 47, 441-450.	1.3	23
240	Iron Metabolism and Iron Supplementation in Anemia of Cancer. Seminars in Hematology, 2006, 43, S13-S17.	3.4	20
241	Keynote comment: Inequalities and shortcomings in European cancer care. Lancet Oncology, The, 2006, 7, 276-277.	10.7	4
242	Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. European Journal of Haematology, 2006, 77, 378-386.	2.2	97
243	Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer, 2006, 107, 2801-2806.	4.1	19
244	Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey. Oncology, 2006, 70, 34-48.	1.9	55
245	Epoetin beta in oncology: examining the current evidence. Future Oncology, 2006, 2, 21-38.	2.4	5
246	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. Oncologist, 2006, 11, 51-61.	3.7	102
247	Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1103-1109.	1.3	49
248	Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.. Blood, 2006, 108, 3398-3398.	1.4	2
249	Deep Vein Thrombosis in Myeloma: Estimate of Prevalence and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).. Blood, 2006, 108, 3571-3571.	1.4	2
250	Monokine Induced by Interferon- γ (MIG) Serum Levels Are a Marker of Disease Load and Correlate with Prognosis in Multiple Myeloma.. Blood, 2006, 108, 5040-5040.	1.4	0
251	Immunoglobulin-Like Transcript 2 (ILT2) Is Not Differentially Expressed in MGUS and Myeloma, but Appears To Be Downregulated at an Earlier Stage of Plasma Cell Disease.. Blood, 2006, 108, 5039-5039.	1.4	0
252	Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m ²) and Triple T with Intermediate Dose Melphalan (100 mg/m ²) in Patients with Multiple Myeloma (An) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5		

#	ARTICLE	IF	CITATIONS
271	Development, Prediction, and Treatment of Anemia in Patients (pts) with Lymphoma/Multiple Myeloma (L/M): Findings of Two European Surveys (ECAS and BEPOS).. Blood, 2004, 104, 3133-3133.	1.4	0
272	Anemia in multiple myeloma. Clinical Advances in Hematology and Oncology, 2004, 2, 233-41.	0.3	39
273	ESMO committed to improving cancer education. Lancet Oncology, The, 2003, 4, 71-72.	10.7	0
274	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398.	1.4	374
275	Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood, 2003, 101, 4137-4139.	1.4	25
276	Reply to Cavill's Letter to the Editor. The Hematology Journal, 2003, 4, 86-86.	1.4	0
277	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-98.	1.4	86
278	Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 852-859.	2.5	24
279	Thalidomide treatment in multiple myeloma. Blood Reviews, 2002, 16, 207-215.	5.7	27
280	Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. The Hematology Journal, 2002, 3, 121-130.	1.4	39
281	Anemia of hematologic malignancies: What are the treatment options?. Seminars in Oncology, 2002, 29, 45-54.	2.2	27
282	Symptomatology of anemia. Seminars in Oncology, 2001, 28, 7-14.	2.2	168
283	Symptomatology of anemia. Seminars in Oncology, 2001, 28, 7-14.	2.2	140
284	Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma. Journal of Clinical Oncology, 2000, 18, 804-804.	1.6	161
285	Trisomy 13 is Associated with Poor Prognosis in Idiopathic Myelofibrosis with Myeloid Metaplasia. Leukemia and Lymphoma, 1999, 35, 415-421.	1.3	7
286	Effect of Interferon Alpha-2a on Hormone Receptor Status in Patients with Advanced Breast Cancer. Cancer Investigation, 1999, 17, 189-194.	1.3	6
287	Expression of CD44 Isoforms on Isolated Bone Marrow Plasma Cells and Peripheral CD19+B Cells of Patients with Multiple Myeloma and Healthy Individuals. Leukemia and Lymphoma, 1999, 34, 95-103.	1.3	6
288	Neurological Function During Long-Term Therapy With Recombinant Interferon Alpha. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 343-348.	1.8	17

#	ARTICLE	IF	CITATIONS
289	Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1998, 103, 1161-1163.	2.5	21
290	Immunohistochemical Evaluation of Cathepsin D Expression in Colorectal Cancer. Cancer Investigation, 1997, 15, 106-110.	1.3	21
291	Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the austrian multicenter phase II study. Leukemia Research, 1997, 21, 75-80.	0.8	30
292	Maximal androgen blockade in combination with methotrexate for treatment of metastatic prostate cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 171-176.	2.5	6
293	About the scientific programme. Annals of Oncology, 1996, 7, iii.	1.2	0
294	Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. Journal of Bone and Mineral Research, 1996, 11, 587-593.	2.8	57
295	Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer, 1995, 76, 2319-2329.	4.1	125
296	Immunological Findings in Patients with Myelodysplastic Syndrome. Leukemia and Lymphoma, 1994, 15, 201-208.	1.3	9
297	Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer, 1994, 73, 2535-2542.	4.1	168
298	The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, andmdr gene expression in colorectal cancer. Cancer, 1993, 71, 2454-2460.	4.1	392
299	Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. British Journal of Haematology, 1993, 84, 428-435.	2.5	30
300	Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells, 1993, 11, 348-355.	3.2	31
301	Interferon- γ Stimulates the Hypothalamic- Pituitary-Adrenal Axis in vivo and in vitro. Neuroendocrinology, 1993, 57, 489-495.	2.5	111
302	MDR1 gene expression and prognostic factors in primary breast carcinomas. European Journal of Cancer & Clinical Oncology, 1991, 27, 1352-1355.	0.7	46
303	Pirarubicin (4?-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. Investigational New Drugs, 1990, 8, 207-10.	2.6	3
304	Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. International Journal of Cancer, 1990, 45, 916-919.	5.1	65
305	Erythropoietin Treatment of Anemia Associated with Multiple Myeloma. New England Journal of Medicine, 1990, 322, 1693-1699.	27.0	456
306	Effect of Recombinant Interferon- γ 2C on Reticuloendothelial Function in Patients with Thrombocytosis. Journal of Interferon Research, 1990, 10, 237-242.	1.2	5

#	ARTICLE	IF	CITATIONS
307	Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. British Journal of Haematology, 1990, 74, 10-16.	2.5	48
308	Early-onset thrombocytopenia during combination chemotherapy in testicular cancer is induced by vinblastine. Cancer, 1989, 63, 51-58.	4.1	4
309	Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunology, Immunotherapy, 1987, 25, 266-73.	4.2	54
310	Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Investigational New Drugs, 1985, 3, 315-8.	2.6	25
311	Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment. Breast Cancer Research and Treatment, 1985, 6, 89-93.	2.5	20
312	A plasma clot culture system for growing and antiproliferative drug sensitivity testing of myeloma stem cells. Leukemia Research, 1984, 8, 701-711.	0.8	8
313	Ultrastructural studies of myeloma cells: Observations concerning the Golgi apparatus and intermediate-size filaments. American Journal of Hematology, 1983, 15, 237-251.	4.1	4
314	In vitro inhibitory effect of interferon on colony formation of myeloma stem cells. Cancer Immunology, Immunotherapy, 1980, 9, 139.	4.2	17
315	Elevated Plasma α_2 -Thromboglobulin Levels in Multiple Myeloma and in Polycythaemia vera. Acta Haematologica, 1979, 62, 219-222.	1.4	11